BTIG on Immunitybio Inc (IBRX): FDA warning letter issue 'likely resolvable,' selloff a buying oppty

March 24, 2026 12:52 PM

BTIG analyst Jeet Mukherjee reiterated a Buy rating and $13.00 price target on Immunitybio Inc (NASDAQ: IBRX)The analyst commented, "IBRX ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found